Sphera Funds Management’s Acceleron Pharma XLRN Stock Holding History

Sphera Funds Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-35,000	Closed	-$1.06M	–	155
2017 Q2	$1.06M	Sell	35,000 -65,000	-65%	-$1.88M	0.18%	104
2017 Q1	$2.65M	Hold	100,000	–	–	0.52%	56
2016 Q4	$2.55M	Buy	+100,000	New	+$3.17M	0.65%	46
2016 Q1	–	Sell	-60,000	Closed	-$2.93M	–	129
2015 Q4	$2.93M	Sell	60,000 -40,000	-40%	-$1.44M	0.43%	59
2015 Q3	$2.49M	Hold	100,000	–	–	0.32%	79
2015 Q2	$3.16M	Buy	+100,000	New	+$3.23M	0.31%	82
2014 Q4	–	Sell	-100,000	Closed	-$3.02M	–	157
2014 Q3	$3.02M	Buy	+100,000	New	+$2.82M	0.37%	64
2014 Q2	–	Sell	-20,000	Closed	-$690K	–	140
2014 Q1	$690K	Sell	20,000 -30,000	-60%	-$1.35M	0.16%	99
2013 Q4	$1.98M	Buy	+50,000	New	+$1.21M	0.55%	47

Other funds holding XLRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Sphera Funds Management's XLRN Position: Q3 2017 in Review

Sphera Funds Management sold out of Acceleron Pharma (XLRN) in Q3 2017, closing a stake of 35,000 shares — an estimated $1.06M sold.

Sphera Funds Management first reported a position in XLRN in Q4 2013 and held it in 9 quarters. The position peaked at $3.16M in Q2 2015. 149 funds tracked by Wall St. Rank hold XLRN as of Q3 2017.

Sphera Funds Management reported no remaining Acceleron Pharma position as of Q3 2017 after selling out during the quarter.
Sphera Funds Management sold 35,000 Acceleron Pharma shares in Q3 2017, an estimated $1.06M.
Sphera Funds Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 9 quarters.
Sphera Funds Management's Acceleron Pharma position peaked at $3.16M in Q2 2015.
149 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2017.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.